Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Henrik U. Andersen

Herlev, DK 
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Herlev, DK 
OverviewLocationsClinical Research

Overview

Henrik Andersen practices in Herlev, Denmark. Mr. Andersen is rated as an Experienced expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Congenital Plasminogen Deficiency, and Type 2 Diabetes (T2D).

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender
Male

Locations

Herlev, Denmark
Other Locations
Odense, Denmark
Copenhagen, Denmark
Gentofte, Denmark
Odense C, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Steno Tech Explore: A Multisite Exploratory Study of People With Type 1 Diabetes on Insulin Pump Therapy
Steno Tech Explore: A Multisite Exploratory Study of People With Type 1 Diabetes on Insulin Pump Therapy
Enrollment Status: Completed
Publish Date: February 01, 2021
Intervention Type: Other
Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases: A Randomised, Placebo-controlled Trial
Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases: A Randomised, Placebo-controlled Trial
Enrollment Status: Completed
Publish Date: July 10, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

86 Total Publications

Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial.
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial.
Journal: Diabetes, obesity & metabolism
Published: August 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Andersen's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile